|
PL170938B1
(pl)
|
1991-03-05 |
1997-02-28 |
Wellcome Found |
Sposób wytwarzania szczepionki przeciwko infekcjom Salmonella PL PL
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
CA2121798C
(en)
|
1991-10-25 |
2007-07-24 |
Richard J. Armitage |
Novel cytokine
|
|
US5962406A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
CA2143299A1
(en)
|
1992-09-04 |
1994-03-17 |
Brenda J. Allan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
AU1059095A
(en)
|
1993-11-24 |
1995-06-13 |
Australian National University, The |
Treatment of viral disease with cd40l peptide
|
|
NZ305083A
(en)
|
1995-03-01 |
1999-06-29 |
Immunex Corp |
Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
|
|
CA2222914C
(en)
|
1995-06-07 |
2002-04-02 |
Immunex Corporation |
Novel cd40l mutein
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6306387B1
(en)
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
CA2313805A1
(en)
|
1997-12-19 |
1999-07-01 |
Immunex Corporation |
Method for reducing susceptibility to hiv infection
|
|
GB9806449D0
(en)
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
IT1299583B1
(it)
|
1998-05-19 |
2000-03-16 |
Vander Way Limited |
Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
|
|
CA2341349C
(en)
|
1998-09-04 |
2013-12-10 |
Creatogen Aktiengesellschaft |
Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
JP2003508016A
(ja)
|
1999-04-16 |
2003-03-04 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
US7118751B1
(en)
|
1999-10-14 |
2006-10-10 |
Trubion Pharmaceuticals, Inc. |
DNA vaccines encoding antigen linked to a domain that binds CD40
|
|
PT1112747E
(pt)
|
1999-12-28 |
2004-10-29 |
Akzo Nobel Nv |
Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
|
|
CA2399790C
(en)
|
2000-02-02 |
2012-10-30 |
Ralph A. Tripp |
Cd40 ligand adjuvant for respiratory syncytial virus
|
|
NZ521425A
(en)
|
2000-03-17 |
2004-05-28 |
Upjohn Co |
Vaccine comprising a first attenuated non-reverting mutant Salmonella in which two or more secretion system apparatus genes have been inactivated
|
|
GB0015426D0
(en)
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
WO2002000232A2
(en)
|
2000-06-26 |
2002-01-03 |
Maxygen, Inc. |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
WO2002036769A2
(en)
|
2000-10-31 |
2002-05-10 |
F. Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US7220723B2
(en)
|
2001-05-15 |
2007-05-22 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
HUP0500042A3
(en)
|
2001-05-15 |
2010-01-28 |
Long Island Jewish Res Inst |
Use of hmg fragments as anti-inflammatory agents
|
|
ES2329453T3
(es)
|
2001-05-15 |
2009-11-26 |
Ortho Mcneil Janssen Pharm |
Cebado ex-vivo para generar linfocitos t citotoxicos especificos del ligando cd40 para tratar enfermedades autoinmunitarias y alergicas.
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
WO2003051383A2
(de)
|
2001-12-19 |
2003-06-26 |
Alcedo Biotech Gmbh |
Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
|
|
MXPA04005909A
(es)
|
2001-12-21 |
2005-05-17 |
Immunex Corp |
Polipeptidos recombinantes.
|
|
AU2003215254A1
(en)
|
2002-02-13 |
2003-09-04 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
|
US6923958B2
(en)
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
WO2003096812A1
(en)
|
2002-04-15 |
2003-11-27 |
Washington University |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
US20040141948A1
(en)
|
2002-11-20 |
2004-07-22 |
Critical Therapeutics, Inc. |
Use of HMGB fragments as anti-inflammatory agents
|
|
AU2003295653B2
(en)
|
2002-11-20 |
2007-08-16 |
The Feinstein Institute Of Medical Research |
Use of HMGB polypeptides for increasing immune responses
|
|
US20040156851A1
(en)
|
2002-11-20 |
2004-08-12 |
Critical Therapeutics, Inc. |
HMGB1 combination therapies
|
|
NZ540067A
(en)
|
2002-11-20 |
2007-05-31 |
Critical Therapeutics Inc |
A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB
|
|
US20050181994A1
(en)
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US20060014248A1
(en)
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US7696169B2
(en)
|
2003-06-06 |
2010-04-13 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005025604A2
(en)
|
2003-09-10 |
2005-03-24 |
The General Hospital Corporation |
Use of hmgb and hmgb fragments to decrease specific immune response
|
|
CA2882022A1
(en)
|
2003-09-11 |
2005-03-24 |
Walter Newman |
Monoclonal antibodies against hmgb1
|
|
WO2005035570A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Variants of cd40l protein
|
|
CN1906210A
(zh)
|
2003-11-21 |
2007-01-31 |
Ace生物科学公司 |
表面定位的空肠弯曲杆菌多肽
|
|
CA2548347A1
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
WO2005103073A2
(en)
|
2004-04-27 |
2005-11-03 |
Intercell Ag |
Td antigens
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
US20080305120A1
(en)
|
2004-06-17 |
2008-12-11 |
Medimmune, Inc. |
Immunogenic Compositions Comprising Hmgb 1 Polypeptides
|
|
CA2559760A1
(en)
*
|
2004-07-02 |
2006-07-06 |
Metanomics Gmbh |
Process for the production of fine chemicals
|
|
EP1814576A2
(en)
|
2004-07-20 |
2007-08-08 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
KR101243577B1
(ko)
|
2004-10-07 |
2013-03-20 |
아고스 쎄라퓨틱스, 인코포레이티드 |
성숙 수지상 세포 조성물 및 그의 배양 방법
|
|
GB0423681D0
(en)
|
2004-10-26 |
2004-11-24 |
Sec Dep For Environment Food & |
Vaccine and nucleic acids
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
WO2006130525A2
(en)
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
|
US20100040608A1
(en)
|
2005-07-18 |
2010-02-18 |
Marie Wahren-Herlenius |
Use of HMGB1 antagonists for the treatment of inflammatory skin conditions
|
|
DE602006014720D1
(de)
|
2005-10-07 |
2010-07-15 |
Proyecto Biomedicina Cima Sl |
Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
|
|
JP2009514536A
(ja)
|
2005-11-07 |
2009-04-09 |
シドニー キンメル キャンサー センター |
Ｃｄ４０リガンド融合蛋白質ワクチン
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
US7829097B2
(en)
|
2006-02-06 |
2010-11-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Use of HMGB1 for protection against ischemia reperfusion injury
|
|
CU23576A1
(es)
|
2006-02-28 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la influenza aviar
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US8802419B2
(en)
|
2006-03-02 |
2014-08-12 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
EP2420832A1
(en)
*
|
2006-05-04 |
2012-02-22 |
Abmaxis, Inc. |
Cross-species and multi-species display systems
|
|
WO2008094197A2
(en)
|
2006-07-27 |
2008-08-07 |
Ligocyte Pharmaceuticals, Inc. |
Chimeric influenza virus-like particles
|
|
JP2010500034A
(ja)
|
2006-08-09 |
2010-01-07 |
メッドイミューン バクシーンズ，インコーポレイティド |
インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
|
|
ES2520026T3
(es)
|
2006-09-18 |
2014-11-11 |
The Board Of Trustees Of The University Of Arkansas |
Composiciones y métodos para potenciar respuestas inmunitarias
|
|
AU2007313819A1
(en)
*
|
2006-10-27 |
2008-05-08 |
Dow Agrosciences Llc |
Poultry vaccine, for necrotic enteritis, comprising a mutated Clostridium perfringens alpha toxin antigen, and methods of producing the vaccine
|
|
US20100292309A1
(en)
|
2007-03-08 |
2010-11-18 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
AU2008275513A1
(en)
|
2007-05-02 |
2009-01-15 |
Emory University |
Enhancement of glycoprotein incorporation into virus-like particles
|
|
BRPI0818736A2
(pt)
|
2007-10-30 |
2017-06-13 |
Univ Arkansas |
composições e métodos para intensificar imunorrepostas à bactéria flagelada
|
|
CN101969990B
(zh)
|
2007-11-01 |
2014-07-09 |
阿肯色大学评议会 |
增强针对艾美球虫属的免疫反应的组合物和方法
|
|
WO2009123737A2
(en)
|
2008-04-03 |
2009-10-08 |
Becton, Dickinson And Company |
Advanced detection of sepsis
|
|
RU2519714C2
(ru)
|
2008-04-30 |
2014-06-20 |
Дженомикс Ко., Лтд. |
Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток
|
|
JP5710482B2
(ja)
|
2008-09-11 |
2015-04-30 |
アンスティテュ・パストゥール |
Ｈｍｇｂ１依存型誘発のｈｉｖ−１複製および持続の調節によるヒト免疫不全ウイルス感染の監視および阻害
|
|
US8163281B2
(en)
|
2009-03-04 |
2012-04-24 |
The Regents Of The University Of Michigan |
Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
|
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
|
CN102811734B
(zh)
|
2010-01-21 |
2016-02-10 |
阿肯色大学评议会 |
增强免疫应答的疫苗载体和方法
|
|
DK2365332T3
(da)
|
2010-03-10 |
2013-08-26 |
Pasteur Institut |
HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser
|
|
US8865653B2
(en)
|
2010-04-22 |
2014-10-21 |
Institut Gustave Roussy |
Method of treatment for immunogenic treatment resistant cancer
|
|
CN102971008B
(zh)
|
2010-06-09 |
2015-11-25 |
阿肯色大学评议会 |
降低弯曲菌属感染的疫苗和方法
|
|
WO2014028776A1
(en)
|
2012-08-15 |
2014-02-20 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
DK2911676T3
(da)
|
2012-10-29 |
2020-08-03 |
Univ Arkansas |
Hidtil ukendte mukosale adjuvanser og afgivelsessystemer
|
|
US9603915B2
(en)
*
|
2013-02-14 |
2017-03-28 |
The Board of Trustees of the University of Akansas |
Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
|
|
BR112015023024B1
(pt)
*
|
2013-03-15 |
2022-04-19 |
The Board Of Trustees Of The University Of Arkansas |
Vetor de vacina e composições farmacêuticas compreendendo o mesmo
|
|
US20170196971A1
(en)
|
2014-06-05 |
2017-07-13 |
The Board Of Trustees Of The University Of Arkansas |
Antibody guided vaccines and methods of use for generation of rapid mature immune responses
|